featured
EASD 2021: SURPASS-5 Demonstrates Promise of Investigational Tirzepatide in Type 2 Diabetes Requiring Basal Insulin
Benefits included improved glycemic control and weight loss without increased risk of hypoglycemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.